Common Stock, $0.0001 par value
- Symbol
- IGC
- Exchange
- NYSEAMER
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
IGC Pharma, Inc.
IGCNYSE_AMERICANEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On July 13, 2026, IGC Pharma, Inc. (“IGC” or the “Company”) furnished an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Company context
IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer’s dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With more than 30 patent filings, 12 patents granted and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Current securities
Registered securities in this filing
IGC PHARMA, INC. · 8-K · Filed 2026-07-14
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On July 13, 2026, IGC Pharma, Inc. (“IGC” or the “Company”)
furnished an updated investor presentation (the “Investor Presentation”). A copy of the Investor Presentation is furnished
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation,
in whole or in part and with modifications or supplements from time to time, in meetings and communications with investors, analysts,
potential strategic partners and others, and at conferences and other business events.
The information contained in the Investor Presentation is summary information
and should be considered in the context of the Company’s filings with the Securities and Exchange Commission and its other public
disclosures. The Investor Presentation speaks only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation
to update or revise the Investor Presentation except as required by applicable law.
The information furnished pursuant to this Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information
therein that is required to be disclosed solely by reason of Regulation FD.
Filed exhibits (1)
EX-99.1 2 igcex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Advancing Alzheimer’s Care. Improving Lives. NYSE American: IGC SAFE HARBOR : Forward - Looking Statements and Important Cautionary Information: This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements include statements regarding the timing, conduct and results of the CALMA Phase 2 trial; the safety and efficacy of IGC - AD1; regulatory and commercialization plans; market opportunities; and the possibility that favor able clinical results or other developments could result in an increase or inflection in IGC Pharma’s valuation. Forward - looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the possibility of delays in enrollment, database l ock or data readout; unfavorable or inconclusive clinical results; safety findings; regulatory delays or denials; financing requirements; competition; and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. Forward …
Open exhibit ↗